scholarly journals Low-Dose Aspirin and Sporadic Anovulation in the EAGeR Randomized Trial

2016 ◽  
Vol 102 (1) ◽  
pp. 86-92 ◽  
Author(s):  
Rose G. Radin ◽  
Lindsey A. Sjaarda ◽  
Neil J. Perkins ◽  
Robert M. Silver ◽  
Zhen Chen ◽  
...  
Keyword(s):  
Pregnancy Loss ◽  
Low Dose ◽  
Controlled Trial ◽  
Double Blind ◽  
Menstrual Cycles ◽  
Spot Urine ◽  
Dose Aspirin ◽  
Low Dose Aspirin ◽  
History Of

Abstract Context: Among women with a single, recent pregnancy loss, daily preconception low-dose aspirin (LDA) increased the live birth rate with no effect on pregnancy loss. Ovulation is a potential mechanism underlying this effect. Objective: We estimated the effect of LDA on the per-cycle risk of anovulation among eumenorrheic women. Design: Multicenter, randomized, double-blind, placebo-controlled trial of daily LDA on reproductive outcomes. Preconception follow-up lasted 1 to 6 menstrual cycles (ClinicalTrials.gov, NCT00467363). Setting: Four US medical centers during 2007 to 2011. Patients or Other Participants: Healthy women (n = 1214), age 18 to 40, were attempting pregnancy, had regular menstrual cycles (21 to 42 days), and had a history of 1 to 2 documented pregnancy losses, ≤2 live births, and no infertility. All participants completed at least 1 menstrual cycle of follow-up; none withdrew due to adverse events. Intervention: Aspirin (81 mg) daily for 1 to 6 menstrual cycles. Main Outcome Measure: Per-cycle risk of anovulation, defined as the absence of both a positive spot-urine pregnancy test and a luteinizing hormone (LH) peak (2.5-fold increase in daily urinary LH). Hypothesis formulation preceded data collection. Results: Among 4340 cycles, LDA was not associated with anovulation (LDA: 13.4%, placebo: 11.1%; risk ratio = 1.16, 95% confidence interval, 0.88 to 1.52). Results were similar among women with a single, recent loss. Conclusions: Daily LDA had no effect on anovulation among women with a history of 1 to 2 pregnancy losses. LDA may affect fertility via other pathways, and these warrant further study.

SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage

Blood ◽  
2010 ◽  
Vol 115 (21) ◽  
pp. 4162-4167 ◽  
Author(s):  
Peter Clark ◽  
Isobel D. Walker ◽  
Peter Langhorne ◽  
Lena Crichton ◽  
Andrew Thomson ◽  
...  
Keyword(s):  
Pregnancy Loss ◽  
Low Dose ◽  
Loss Rate ◽  
Controlled Trial ◽  
Previous Pregnancy ◽  
Randomized Controlled ◽  
Dose Aspirin ◽  
Low Dose Aspirin ◽  
Multicenter Randomized Controlled Trial ◽  
History Of

To assess whether treatment with enoxaparin and low-dose aspirin, along with intensive pregnancy surveillance, reduces rate of pregnancy loss compared with intensive pregnancy surveillance alone in women with history of 2 or more consecutive previous pregnancy losses, a parallel group, multicenter, randomized controlled trial was performed in the United Kingdom and New Zealand. Participants (n = 294) presenting for initial antenatal care at fewer than 7 weeks' gestation with history of 2 or more consecutive previous pregnancy losses at 24 or fewer weeks' gestation and no evidence of anatomic, endocrine, chromosomal, or immunologic abnormality were randomly assigned to receive either enoxaparin 40 mg subcutaneously and 75 mg of aspirin orally once daily along with intense pregnancy surveillance or intense pregnancy surveillance alone from random assignment until 36 weeks' gestation. The primary outcome measure was pregnancy loss rate. Of the 147 participants receiving pharmacologic intervention, 32 (22%) pregnancy losses occurred, compared with 29 losses (20%) in the 147 subjects receiving intensive surveillance alone, giving an odds ratio of 0.91 (95% confidence interval, 0.52-1.59) of having a successful pregnancy with pharmacologic intervention. Thus, we observed no reduction in pregnancy loss rate with antithrombotic intervention in pregnant women with 2 or more consecutive previous pregnancy losses. The trial was registered at http://www.controlled-trials.com as ISRCTN06774126.

scholarly journals Does low-dose aspirin improve pregnancy rate in IVF/ICSI? A randomized double-blind placebo controlled trial

2008 ◽  
Vol 24 (4) ◽  
pp. 856-860 ◽  
Author(s):  
K. Dirckx ◽  
P. Cabri ◽  
A. Merien ◽  
L. Galajdova ◽  
J. Gerris ◽  
...  
Keyword(s):  
Pregnancy Rate ◽  
Low Dose ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Dose Aspirin ◽  
Low Dose Aspirin

scholarly journals The effect of low-dose aspirin on frailty phenotype and frailty index in community-dwelling older adults in the ASPirin in Reducing Events in the Elderly study

2021 ◽  
Author(s):  
Sara E Espinoza ◽  
Robyn L Woods ◽  
A R M Saifuddin Ekram ◽  
Michael E Ernst ◽  
Galina Polekhina ◽  
...  
Keyword(s):  
Older Adults ◽  
Low Dose ◽  
Controlled Trial ◽  
Frailty Index ◽  
The Elderly ◽  
Community Dwelling ◽  
Study Endpoint ◽  
Double Blind ◽  
Dose Aspirin ◽  
Low Dose Aspirin

Abstract BACKGROUND Frailty is associated with chronic inflammation, which may be modified by aspirin. The purpose of this study was to determine whether low dose aspirin reduces incident frailty in healthy older adult participants of the ASPirin in Reducing Events in the Elderly (ASPREE) trial. METHODS In the U.S and Australia, 19,114 community-dwelling individuals aged ≥70 years (U.S minorities ≥65 years) and free of overt cardiovascular disease, persistent physical disability, and dementia, were enrolled in ASPREE, a double-blind, placebo-controlled trial of 100mg daily aspirin versus placebo. Frailty, a pre-specified study endpoint, was defined according to a modified Fried frailty definition (Fried frailty) and the frailty index based on the deficit accumulation model (frailty index). Competing risk Cox proportional hazards models were used to compare time to incident frailty by aspirin versus placebo. Sensitivity analysis was conducted to include frailty data with and without imputation of missing data. RESULTS Over a median 4.7 years, 2252 participants developed incident Fried frailty, and 4451 had incident frailty according to the frailty index. Compared with placebo, aspirin treatment did not alter the risk of incident frailty (Fried frailty HR: 1.04, 95% CI 0.96-1.13; frailty index HR: 1.03, 95% CI 0.97-1.09). The proportion of individuals classified as frail, and the trajectory in continuous frailty scores over time, were not different between the aspirin and placebo treatment groups. The results were consistent across a series of subgroups. CONCLUSIONS Low dose aspirin use in healthy older adults when initiated in older ages does not reduce risk of incident frailty or the trajectory of frailty.

scholarly journals Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled trial

The Lancet ◽  
2020 ◽  
Vol 395 (10220) ◽  
pp. 285-293 ◽  
Author(s):  
Matthew K Hoffman ◽  
Shivaprasad S Goudar ◽  
Bhalachandra S Kodkany ◽  
Mrityunjay Metgud ◽  
Manjunath Somannavar ◽  
...  
Keyword(s):  
Preterm Delivery ◽  
Low Dose ◽  
Controlled Trial ◽  
Singleton Pregnancy ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Dose Aspirin ◽  
Nulliparous Women ◽  
Low Dose Aspirin

scholarly journals A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of High-Dose Rebamipide Treatment for Low-Dose Aspirin-Induced Moderate-to-Severe Small Intestinal Damage

PLoS ONE ◽  
2015 ◽  
Vol 10 (4) ◽  
pp. e0122330 ◽  
Author(s):  
Toshio Watanabe ◽  
Toshihisa Takeuchi ◽  
Osamu Handa ◽  
Yasuhisa Sakata ◽  
Tetsuya Tanigawa ◽  
...  
Keyword(s):  
Low Dose ◽  
Controlled Trial ◽  
High Dose ◽  
Intestinal Damage ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Dose Aspirin ◽  
Low Dose Aspirin ◽  
Small Intestinal
Sign in / Sign up

Export Citation Format

Share Document